Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3013753 | 0.80 | ROCK2 (0.47) | — | |
| SCHEMBL3015928 | 0.78 | SLC6A2 (0.49) | SLC6A4SLC6A3SLC6A2CYP2D6CA1 | |
| SCHEMBL3016545 | 0.78 | SLC6A2 (0.46) | SLC6A4SLC6A3SLC6A2CYP2D6HTR2A | |
| SCHEMBL7827207 | 0.78 | SLC6A4 (0.66) | SLC6A4SLC6A3SLC6A2CYP2D6CA1 | |
| SCHEMBL2951055 | 0.77 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6CA1 | |
| SCHEMBL14255967 | 0.76 | SLC6A4 (0.63) | SLC6A4SLC6A3SLC6A2CYP2D6CA1 | |
| SCHEMBL11199899 | 0.75 | L3MBTL1 (0.37) | SLC6A4SLC6A3SLC6A2HTR2AHTR2C | |
| SCHEMBL778752 | 0.75 | CHRNA7 (0.59) | — | |
| SCHEMBL2941780 | 0.74 | SLC6A4 (0.66) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| Hydrochloric Acid SCHEMBL3939474 | 0.74 | CHRNA7 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
| EP-2188272-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV Remynd (BE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009019295-A3 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | SLC6A4 731/4885SLC6A3 111/4885SLC6A2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.